Skip to main content
. Author manuscript; available in PMC: 2013 Jun 20.
Published in final edited form as: J Neuroimmune Pharmacol. 2012 May 5;7(3):629–639. doi: 10.1007/s11481-012-9369-9

Figure 5.

Figure 5

Pharmacological profiles of vesicular [3H]DA uptake in rat striatum in the presence of Tat1–86, Tat Cys22, or tetrabenazine (TBZ, a VMAT2 inhibitor). Striatal synaptosomes were preincubated with various concentrations of Tat1–86, Tat Cys22, or TBZ (0.1 nM–10 µM) at 34°C for 15 min followed by the addition of [3H]DA (final concentration, 0.1 µM) for 8 min. Tat Cys22 and TBZ were used as negative and positive controls, respectively. Data are expressed as mean ± S.E.M. as percentage of control (CON) values (28,205 ± 1965 dpm) from five independent experiments performed in duplicate. Nonspecific [3H]DA uptake was determined in the presence of 10 µM nomifensine. All curves were best fit to a single class of binding site and generated by nonlinear regression.